<s id="wsj_1066.1"> 36
1 	 0 	 N/N 	 1 	 Inc. Delmed
1 	 2 	 (NP[nb]/N)\NP 	 2 	 Inc. 's
5 	 2 	 (NP[nb]/N)\NP 	 1 	 officers 's
5 	 3 	 N/N 	 1 	 officers top
5 	 4 	 N/N 	 1 	 officers two
5 	 6 	 S[dcl]\NP 	 1 	 officers resigned
5 	 8 	 (S[dcl]\NP)/(S[pss]\NP) 	 1 	 officers were <XU>
5 	 9 	 S[pss]\NP 	 1 	 officers succeeded <XU>
9 	 8 	 (S[dcl]\NP)/(S[pss]\NP) 	 2 	 succeeded were
9 	 10 	 ((S\NP)\(S\NP))/NP 	 2 	 succeeded by
11 	 10 	 ((S\NP)\(S\NP))/NP 	 3 	 executives by
11 	 12 	 (NP\NP)/NP 	 1 	 executives of
15 	 12 	 (NP\NP)/NP 	 2 	 Inc. of
15 	 13 	 N/N 	 1 	 Inc. Fresenius
15 	 14 	 N/N 	 1 	 Inc. USA
18 	 12 	 (NP\NP)/NP 	 2 	 parent of
18 	 17 	 NP[nb]/N 	 1 	 parent its
21 	 12 	 (NP\NP)/NP 	 2 	 AG of
21 	 20 	 N/N 	 1 	 AG Fresenius
26 	 12 	 (NP\NP)/NP 	 2 	 holder of
26 	 23 	 NP[nb]/N 	 1 	 holder a
26 	 24 	 N/N 	 1 	 holder major
26 	 25 	 N/N 	 1 	 holder Delmed
26 	 27 	 (NP\NP)/(S[dcl]\NP) 	 1 	 holder that
26 	 28 	 (S[dcl]\NP)/(S[pt]\NP) 	 1 	 holder has <XB>
26 	 30 	 (S[ng]\NP)/(S[to]\NP) 	 1 	 holder negotiating <XB>
26 	 32 	 (S[b]\NP)/NP 	 1 	 holder acquire <XB>
28 	 27 	 (NP\NP)/(S[dcl]\NP) 	 2 	 has that
29 	 28 	 (S[dcl]\NP)/(S[pt]\NP) 	 2 	 been has
30 	 29 	 (S[pt]\NP)/(S[ng]\NP) 	 2 	 negotiating been
31 	 30 	 (S[ng]\NP)/(S[to]\NP) 	 2 	 to negotiating
32 	 31 	 (S[to]\NP)/(S[b]\NP) 	 2 	 acquire to
35 	 32 	 (S[b]\NP)/NP 	 2 	 stake acquire
35 	 33 	 NP[nb]/N 	 1 	 stake a
35 	 34 	 N/N 	 1 	 stake controlling
<\s>
<s id="wsj_1066.2"> 35
1 	 0 	 (S/S)/NP 	 2 	 addition In
3 	 5 	 (NP\NP)/(S[dcl]\NP) 	 1 	 Delmed which
3 	 6 	 (S[dcl]\NP)/NP 	 1 	 Delmed makes <XB>
3 	 8 	 (S[dcl]\NP)/NP 	 1 	 Delmed sells <XU>
3 	 18 	 (S[dcl]\NP)/S[dcl] 	 1 	 Delmed said
6 	 5 	 (NP\NP)/(S[dcl]\NP) 	 2 	 makes which
8 	 5 	 (NP\NP)/(S[dcl]\NP) 	 2 	 sells which
11 	 6 	 (S[dcl]\NP)/NP 	 2 	 solution makes <XU>
11 	 8 	 (S[dcl]\NP)/NP 	 2 	 solution sells
11 	 9 	 NP[nb]/N 	 1 	 solution a
11 	 10 	 N/N 	 1 	 solution dialysis
11 	 12 	 S[pss]\NP 	 1 	 solution used <XB>
11 	 14 	 (S[ng]\NP)/NP 	 1 	 solution treating <XB>
12 	 13 	 ((S\NP)\(S\NP))/(S[ng]\NP) 	 2 	 used in
14 	 13 	 ((S\NP)\(S\NP))/(S[ng]\NP) 	 3 	 treating in
16 	 14 	 (S[ng]\NP)/NP 	 2 	 diseases treating
16 	 15 	 N/N 	 1 	 diseases kidney
18 	 0 	 (S/S)/NP 	 1 	 said In
19 	 20 	 (NP\NP)/NP 	 1 	 negotiations about
19 	 22 	 (S[dcl]\NP)/(S[pt]\NP) 	 1 	 negotiations had
19 	 23 	 S[pt]\NP 	 1 	 negotiations collapsed <XB>
21 	 20 	 (NP\NP)/NP 	 2 	 pricing about
22 	 18 	 (S[dcl]\NP)/S[dcl] 	 2 	 had said
23 	 22 	 (S[dcl]\NP)/(S[pt]\NP) 	 2 	 collapsed had
23 	 24 	 ((S\NP)\(S\NP))/NP 	 2 	 collapsed between
25 	 24 	 ((S\NP)\(S\NP))/NP 	 3 	 it between
29 	 24 	 ((S\NP)\(S\NP))/NP 	 3 	 distributor between
29 	 27 	 NP[nb]/N 	 1 	 distributor a
29 	 28 	 N/N 	 1 	 distributor major
34 	 24 	 ((S\NP)\(S\NP))/NP 	 3 	 Inc between
34 	 31 	 N/N 	 1 	 Inc National
34 	 32 	 N/N 	 1 	 Inc Medical
34 	 33 	 N/N 	 1 	 Inc Care
<\s>
<s id="wsj_1066.3"> 13
0 	 1 	 (S[dcl]\NP)/S[dcl] 	 1 	 Delmed said
4 	 2 	 N/N 	 1 	 Ehrlich Robert
4 	 3 	 N/N 	 1 	 Ehrlich S.
4 	 5 	 (S[dcl]\NP)/PP 	 1 	 Ehrlich resigned
5 	 1 	 (S[dcl]\NP)/S[dcl] 	 2 	 resigned said
6 	 5 	 (S[dcl]\NP)/PP 	 2 	 as resigned
7 	 6 	 PP/NP 	 1 	 chairman as
9 	 6 	 PP/NP 	 1 	 president as
12 	 6 	 PP/NP 	 1 	 executive as
12 	 11 	 N/N 	 1 	 executive chief
<\s>
<s id="wsj_1066.4"> 10
1 	 0 	 N/N 	 1 	 Ehrlich Mr.
1 	 2 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 Ehrlich will
1 	 3 	 (S[b]\NP)/PP 	 1 	 Ehrlich continue <XB>
3 	 2 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 continue will
4 	 3 	 (S[b]\NP)/PP 	 2 	 as continue
6 	 4 	 PP/NP 	 1 	 director as
6 	 5 	 NP[nb]/N 	 1 	 director a
9 	 4 	 PP/NP 	 1 	 consultant as
9 	 8 	 NP[nb]/N 	 1 	 consultant a
<\s>
<s id="wsj_1066.5"> 18
2 	 0 	 N/N 	 1 	 Shapiro Leslie
2 	 1 	 N/N 	 1 	 Shapiro I.
2 	 13 	 S[dcl]\NP 	 1 	 Shapiro resigned
6 	 4 	 N/N 	 1 	 officer chief
6 	 5 	 N/N 	 1 	 officer operating
6 	 13 	 S[dcl]\NP 	 1 	 officer resigned
10 	 8 	 N/N 	 1 	 officer chief
10 	 9 	 N/N 	 1 	 officer financial
10 	 13 	 S[dcl]\NP 	 1 	 officer resigned
13 	 12 	 (S\NP)/(S\NP) 	 2 	 resigned also
13 	 17 	 (S[dcl]\S[dcl])\NP 	 1 	 resigned said
16 	 15 	 NP[nb]/N 	 1 	 company the
16 	 17 	 (S[dcl]\S[dcl])\NP 	 2 	 company said
<\s>
<s id="wsj_1066.6"> 20
1 	 0 	 N/N 	 1 	 Ehrlich Mr.
1 	 2 	 (S[dcl]\NP)/(S[pss]\NP) 	 1 	 Ehrlich was
1 	 3 	 (S[pss]\NP)/PP 	 1 	 Ehrlich succeeded <XB>
3 	 2 	 (S[dcl]\NP)/(S[pss]\NP) 	 2 	 succeeded was
3 	 6 	 ((S\NP)\(S\NP))/NP 	 2 	 succeeded by
4 	 3 	 (S[pss]\NP)/PP 	 2 	 as succeeded
5 	 4 	 PP/NP 	 1 	 chairman as
8 	 6 	 ((S\NP)\(S\NP))/NP 	 3 	 Krick by
8 	 7 	 N/N 	 1 	 Krick Gerd
11 	 6 	 ((S\NP)\(S\NP))/NP 	 3 	 director by
11 	 10 	 NP[nb]/N 	 1 	 director a
11 	 12 	 (NP\NP)/NP 	 1 	 director of
13 	 12 	 (NP\NP)/NP 	 2 	 Fresenius of
17 	 16 	 (N/N)/(N/N) 	 2 	 German West
19 	 12 	 (NP\NP)/NP 	 2 	 concern of
19 	 15 	 NP[nb]/N 	 1 	 concern a
19 	 17 	 N/N 	 1 	 concern German
19 	 18 	 N/N 	 1 	 concern pharmaceutical
<\s>
<s id="wsj_1066.7"> 18
1 	 0 	 N/N 	 1 	 Lipps Ben
1 	 8 	 (S[dcl]\NP)/(S[pss]\NP) 	 1 	 Lipps was
1 	 9 	 (S[pss]\NP)/NP 	 1 	 Lipps named <XB>
3 	 4 	 (NP\NP)/NP 	 1 	 president of
3 	 8 	 (S[dcl]\NP)/(S[pss]\NP) 	 1 	 president was
3 	 9 	 (S[pss]\NP)/NP 	 1 	 president named <XB>
6 	 4 	 (NP\NP)/NP 	 2 	 USA of
6 	 5 	 N/N 	 1 	 USA Fresenius
9 	 8 	 (S[dcl]\NP)/(S[pss]\NP) 	 2 	 named was
10 	 9 	 (S[pss]\NP)/NP 	 2 	 president named
13 	 9 	 (S[pss]\NP)/NP 	 2 	 executive named
13 	 12 	 N/N 	 1 	 executive chief
17 	 9 	 (S[pss]\NP)/NP 	 2 	 officer named
17 	 15 	 N/N 	 1 	 officer chief
17 	 16 	 N/N 	 1 	 officer operating
<\s>
<s id="wsj_1066.8"> 8
0 	 1 	 (NP\NP)/NP 	 1 	 None of
0 	 4 	 (S[dcl]\NP)/(S[adj]\NP) 	 1 	 None was
0 	 5 	 (S[adj]\NP)/PP 	 1 	 None available <XB>
3 	 1 	 (NP\NP)/NP 	 2 	 officials of
3 	 2 	 NP[nb]/N 	 1 	 officials the
5 	 4 	 (S[dcl]\NP)/(S[adj]\NP) 	 2 	 available was
6 	 5 	 (S[adj]\NP)/PP 	 2 	 for available
7 	 6 	 PP/NP 	 1 	 comment for
<\s>
<s id="wsj_1066.9"> 17
1 	 0 	 (S/S)/NP 	 2 	 trading In
1 	 2 	 (NP\NP)/NP 	 1 	 trading on
6 	 2 	 (NP\NP)/NP 	 2 	 Exchange on
6 	 3 	 NP[nb]/N 	 1 	 Exchange the
6 	 4 	 N/N 	 1 	 Exchange American
6 	 5 	 N/N 	 1 	 Exchange Stock
8 	 9 	 ((S[dcl]\NP)/(S[adj]\NP))/PP 	 1 	 Delmed closed
8 	 14 	 (S[adj]\NP)/NP 	 1 	 Delmed down <XB>
9 	 0 	 (S/S)/NP 	 1 	 closed In
10 	 9 	 ((S[dcl]\NP)/(S[adj]\NP))/PP 	 3 	 at closed
12 	 10 	 PP/NP 	 1 	 cents at
12 	 11 	 N/N 	 1 	 cents 50
14 	 9 	 ((S[dcl]\NP)/(S[adj]\NP))/PP 	 2 	 down closed
16 	 14 	 (S[adj]\NP)/NP 	 2 	 cents down
16 	 15 	 N/N 	 1 	 cents 6.25
<\s>
<s id="wsj_1066.10"> 12
0 	 1 	 (S[dcl]\NP)/NP 	 1 	 Fresenius owns
3 	 2 	 (N/N)/(N/N) 	 2 	 42 about
4 	 1 	 (S[dcl]\NP)/NP 	 2 	 % owns
4 	 3 	 N/N 	 1 	 % 42
4 	 5 	 (NP\NP)/NP 	 1 	 % of
6 	 7 	 (NP[nb]/N)\NP 	 2 	 Delmed 's
9 	 8 	 (N/N)/(N/N) 	 2 	 diluted fully
11 	 5 	 (NP\NP)/NP 	 2 	 stock of
11 	 7 	 (NP[nb]/N)\NP 	 1 	 stock 's
11 	 9 	 N/N 	 1 	 stock diluted
11 	 10 	 N/N 	 1 	 stock common
<\s>
<s id="wsj_1066.11"> 36
2 	 0 	 NP[nb]/N 	 1 	 companies The
2 	 1 	 N/N 	 1 	 companies two
2 	 3 	 (S[dcl]\NP)/(S[pt]\NP) 	 1 	 companies have
2 	 5 	 (S[ng]\NP)/NP 	 1 	 companies discussing <XB>
4 	 3 	 (S[dcl]\NP)/(S[pt]\NP) 	 2 	 been have
5 	 4 	 (S[pt]\NP)/(S[ng]\NP) 	 2 	 discussing been
7 	 5 	 (S[ng]\NP)/NP 	 2 	 transaction discussing
7 	 6 	 NP[nb]/N 	 1 	 transaction a
7 	 9 	 ((NP\NP)/S[dcl])\((NP\NP)/NP) 	 1 	 transaction which
8 	 9 	 ((NP\NP)/S[dcl])\((NP\NP)/NP) 	 3 	 under which
10 	 11 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 Fresenius would
10 	 12 	 ((S[b]\NP)/PP)/NP 	 1 	 Fresenius buy <XB>
10 	 18 	 ((S[b]\NP)/PP)/NP 	 1 	 Fresenius bring <XB>
11 	 9 	 ((NP\NP)/S[dcl])\((NP\NP)/NP) 	 2 	 would which
12 	 11 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 buy would
14 	 12 	 ((S[b]\NP)/PP)/NP 	 3 	 stock buy
14 	 13 	 N/N 	 1 	 stock Delmed
15 	 12 	 ((S[b]\NP)/PP)/NP 	 2 	 for buy
16 	 15 	 PP/NP 	 1 	 cash for
18 	 17 	 (S[to]\NP)/(S[b]\NP) 	 2 	 bring to
21 	 18 	 ((S[b]\NP)/PP)/NP 	 3 	 ownership bring
21 	 19 	 NP[nb]/N 	 1 	 ownership its
21 	 20 	 N/N 	 1 	 ownership beneficial
22 	 18 	 ((S[b]\NP)/PP)/NP 	 2 	 to bring
25 	 22 	 PP/NP 	 1 	 % to
25 	 23 	 N/N 	 1 	 % between
25 	 24 	 N/N 	 1 	 % 70
25 	 29 	 (NP\NP)/NP 	 1 	 % of
28 	 22 	 PP/NP 	 1 	 % to
28 	 23 	 N/N 	 1 	 % between
28 	 27 	 N/N 	 1 	 % 80
28 	 29 	 (NP\NP)/NP 	 1 	 % of
30 	 31 	 (NP[nb]/N)\NP 	 2 	 Delmed 's
33 	 32 	 (N/N)/(N/N) 	 2 	 diluted fully
35 	 29 	 (NP\NP)/NP 	 2 	 stock of
35 	 31 	 (NP[nb]/N)\NP 	 1 	 stock 's
35 	 33 	 N/N 	 1 	 stock diluted
35 	 34 	 N/N 	 1 	 stock common
<\s>
<s id="wsj_1066.12"> 9
1 	 0 	 NP[nb]/N 	 1 	 transaction The
1 	 3 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 transaction would
1 	 4 	 (S[b]\NP)/NP 	 1 	 transaction combine <XB>
3 	 2 	 (S\NP)/(S\NP) 	 2 	 would also
4 	 3 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 combine would
6 	 4 	 (S[b]\NP)/NP 	 2 	 USA combine
6 	 5 	 N/N 	 1 	 USA Fresenius
8 	 4 	 (S[b]\NP)/NP 	 2 	 Delmed combine
<\s>
<s id="wsj_1066.13"> 37
2 	 0 	 (S/S)/NP 	 2 	 proposal Under
2 	 1 	 NP[nb]/N 	 1 	 proposal the
4 	 5 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 Delmed would
4 	 6 	 (((S[b]\NP)/PP)/PP)/NP 	 1 	 Delmed issue <XB>
5 	 0 	 (S/S)/NP 	 1 	 would Under
6 	 5 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 issue would
9 	 7 	 (N/N)/(N/N) 	 2 	 million about
9 	 8 	 (N/N)/(N/N) 	 2 	 million 123.5
13 	 6 	 (((S[b]\NP)/PP)/PP)/NP 	 4 	 shares issue
13 	 9 	 N/N 	 1 	 shares million
13 	 10 	 N/N 	 1 	 shares additional
13 	 11 	 N/N 	 1 	 shares Delmed
13 	 12 	 N/N 	 1 	 shares common
14 	 6 	 (((S[b]\NP)/PP)/PP)/NP 	 3 	 to issue
15 	 14 	 PP/NP 	 1 	 Fresenius to
16 	 6 	 (((S[b]\NP)/PP)/PP)/NP 	 2 	 at issue
19 	 16 	 PP/NP 	 1 	 price at
19 	 17 	 NP[nb]/N 	 1 	 price an
19 	 18 	 N/N 	 1 	 price average
19 	 20 	 (NP\NP)/NP 	 1 	 price of
22 	 21 	 (N/N)/(N/N) 	 2 	 65 about
23 	 20 	 (NP\NP)/NP 	 2 	 cents of
23 	 22 	 N/N 	 1 	 cents 65
23 	 24 	 (NP\NP)/N 	 1 	 cents a
23 	 27 	 (NP\NP)/NP 	 1 	 cents though
25 	 24 	 (NP\NP)/N 	 2 	 share a
30 	 28 	 (NP/NP)/NP 	 2 	 circumstances under
30 	 29 	 NP[nb]/N 	 1 	 circumstances no
31 	 32 	 ((N/N)/(N/N))\(S[adj]\NP) 	 3 	 more than
33 	 32 	 ((N/N)/(N/N))\(S[adj]\NP) 	 2 	 75 than
34 	 27 	 (NP\NP)/NP 	 2 	 cents though
34 	 28 	 (NP/NP)/NP 	 1 	 cents under
34 	 33 	 N/N 	 1 	 cents 75
34 	 35 	 (NP\NP)/N 	 1 	 cents a
36 	 35 	 (NP\NP)/N 	 2 	 share a
<\s>
<s id="wsj_1066.14"> 16
2 	 3 	 (S[dcl]\NP)/S[dcl] 	 1 	 Delmed said
3 	 0 	 S/S 	 1 	 said Yesterday
4 	 5 	 (S[dcl]\NP)/(S[to]\NP) 	 1 	 it continues
4 	 7 	 (S[b]\NP)/NP 	 1 	 it explore <XB>
5 	 3 	 (S[dcl]\NP)/S[dcl] 	 2 	 continues said
6 	 5 	 (S[dcl]\NP)/(S[to]\NP) 	 2 	 to continues
7 	 6 	 (S[to]\NP)/(S[b]\NP) 	 2 	 explore to
9 	 7 	 (S[b]\NP)/NP 	 2 	 possibility explore
9 	 8 	 NP[nb]/N 	 1 	 possibility the
9 	 10 	 (NP\NP)/NP 	 1 	 possibility of
12 	 10 	 (NP\NP)/NP 	 2 	 combination of
12 	 11 	 NP[nb]/N 	 1 	 combination a
12 	 13 	 (NP\NP)/NP 	 1 	 combination with
15 	 13 	 (NP\NP)/NP 	 2 	 USA with
15 	 14 	 N/N 	 1 	 USA Fresenius
<\s>
<s id="wsj_1066.15"> 21
0 	 1 	 (S[dcl]\NP)/S[em] 	 1 	 It added
2 	 1 	 (S[dcl]\NP)/S[em] 	 2 	 that added
3 	 4 	 ((S[dcl]\NP[expl])/S[em])/(S[adj]\NP) 	 1 	 it is
4 	 2 	 S[em]/S[dcl] 	 1 	 is that
5 	 4 	 ((S[dcl]\NP[expl])/S[em])/(S[adj]\NP) 	 3 	 apparent is
6 	 4 	 ((S[dcl]\NP[expl])/S[em])/(S[adj]\NP) 	 2 	 that is
8 	 7 	 NP[nb]/N 	 1 	 terms any
8 	 9 	 (NP\NP)/NP 	 1 	 terms of
8 	 12 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 terms would
8 	 16 	 S[adj]\NP 	 1 	 terms favorable <XB>
11 	 9 	 (NP\NP)/NP 	 2 	 combination of
11 	 10 	 NP[nb]/N 	 1 	 combination a
12 	 6 	 S[em]/S[dcl] 	 1 	 would that
13 	 12 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 be would
16 	 13 	 (S[b]\NP)/(S[adj]\NP) 	 2 	 favorable be
16 	 14 	 (S[adj]\NP)/(S[adj]\NP) 	 2 	 favorable substantially
16 	 15 	 (S[adj]\NP)/(S[adj]\NP) 	 2 	 favorable less
16 	 17 	 ((S[adj]\NP)\(S[adj]\NP))/NP 	 2 	 favorable than
18 	 17 	 ((S[adj]\NP)\(S[adj]\NP))/NP 	 3 	 those than
18 	 20 	 S[pss]\NP 	 1 	 those announced <XB>
20 	 19 	 (S\NP)/(S\NP) 	 2 	 announced previously
<\s>
<s id="wsj_1066.16"> 34
2 	 1 	 NP[nb]/N 	 1 	 discussions the
2 	 3 	 (NP\NP)/NP 	 1 	 discussions between
2 	 9 	 (S[dcl]\NP)/(S[pt]\NP) 	 1 	 discussions have
2 	 11 	 S[pss]\NP 	 1 	 discussions discontinued <XB>
4 	 3 	 (NP\NP)/NP 	 2 	 Delmed between
8 	 3 	 (NP\NP)/NP 	 2 	 Care between
8 	 6 	 N/N 	 1 	 Care National
8 	 7 	 N/N 	 1 	 Care Medical
9 	 0 	 (S/S)/S[dcl] 	 2 	 have While
10 	 9 	 (S[dcl]\NP)/(S[pt]\NP) 	 2 	 been have
11 	 10 	 (S[pt]\NP)/(S[pss]\NP) 	 2 	 discontinued been
13 	 14 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 Delmed will
13 	 15 	 (S[b]\NP)/(S[to]\NP) 	 1 	 Delmed continue <XB>
13 	 17 	 (S[b]\NP)/NP 	 1 	 Delmed supply <XB>
14 	 0 	 (S/S)/S[dcl] 	 1 	 will While
14 	 33 	 (S[dcl]\S[dcl])\NP 	 1 	 will said
15 	 14 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 continue will
15 	 23 	 ((S\NP)\(S\NP))/S[dcl] 	 2 	 continue after
16 	 15 	 (S[b]\NP)/(S[to]\NP) 	 2 	 to continue
17 	 16 	 (S[to]\NP)/(S[b]\NP) 	 2 	 supply to
17 	 20 	 ((S\NP)\(S\NP))/NP 	 2 	 supply through
19 	 17 	 (S[b]\NP)/NP 	 2 	 products supply
19 	 18 	 N/N 	 1 	 products dialysis
22 	 20 	 ((S\NP)\(S\NP))/NP 	 3 	 Medical through
22 	 21 	 N/N 	 1 	 Medical National
26 	 24 	 NP[nb]/N 	 1 	 agreement their
26 	 25 	 N/N 	 1 	 agreement exclusive
26 	 27 	 S[dcl]\NP 	 1 	 agreement ends
27 	 23 	 ((S\NP)\(S\NP))/S[dcl] 	 3 	 ends after
27 	 28 	 ((S\NP)\(S\NP))/NP 	 2 	 ends in
29 	 28 	 ((S\NP)\(S\NP))/NP 	 3 	 March in
29 	 30 	 N\N 	 1 	 March 1990
32 	 33 	 (S[dcl]\S[dcl])\NP 	 2 	 Delmed said
<\s>
<s id="wsj_1066.17"> 14
1 	 0 	 (S/S)/NP 	 2 	 addition In
3 	 4 	 (S[dcl]\NP)/(S[ng]\NP) 	 1 	 Delmed is
3 	 5 	 (S[ng]\NP)/NP 	 1 	 Delmed exploring <XB>
4 	 0 	 (S/S)/NP 	 1 	 is In
4 	 13 	 (S[dcl]\S[dcl])\NP 	 1 	 is said
5 	 4 	 (S[dcl]\NP)/(S[ng]\NP) 	 2 	 exploring is
5 	 8 	 ((S\NP)\(S\NP))/NP 	 2 	 exploring with
7 	 5 	 (S[ng]\NP)/NP 	 2 	 arrangements exploring
7 	 6 	 N/N 	 1 	 arrangements distribution
10 	 8 	 ((S\NP)\(S\NP))/NP 	 3 	 USA with
10 	 9 	 N/N 	 1 	 USA Fresenius
12 	 13 	 (S[dcl]\S[dcl])\NP 	 2 	 Delmed said
<\s>
